Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Athersys Inc (ATHX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 292,404
  • Shares Outstanding, K 138,580
  • Annual Sales, $ 3,710 K
  • Annual Income, $ -32,240 K
  • 36-Month Beta -0.61
  • Price/Sales 80.35
  • Price/Cash Flow N/A
  • Price/Book 5.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.08
  • Number of Estimates 1
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.83 +12.77%
on 09/21/18
2.23 -7.46%
on 09/26/18
+0.19 (+10.35%)
since 09/18/18
3-Month
1.83 +12.77%
on 09/21/18
2.23 -7.46%
on 09/26/18
+0.06 (+3.18%)
since 07/18/18
52-Week
1.29 +59.97%
on 03/02/18
3.09 -33.22%
on 06/07/18
+0.12 (+6.10%)
since 10/18/17

Most Recent Stories

More News
Athersys to Host Third Quarter Financial Results Call

Athersys, Inc. (NASDAQ: ATHX) will release its third quarter 2018 financial results at approximately 4:00 p.m. Eastern Time on Tuesday, November 6th, 2018, and will host a conference call shortly thereafter...

ATHX : 2.06 (-2.37%)
Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%

Audentes Therapeutics (BOLD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

BOLD : 27.43 (-2.97%)
ATHX : 2.06 (-2.37%)
Increasing Number of Cancer Cases to Fuel the Global Cancer Immunotherapy Market Growth

According to data compiled by Transparency Market Research, the global cancer immunotherapy market is expected to grow from USD 37.50 Billion in 2015 to USD 124.88 Billion by 2024 while registering a CAGR...

RGBP : 0.0099 (-13.91%)
CRIS : 2.10 (-6.67%)
BPTH : 0.55 (unch)
ATHX : 2.06 (-2.37%)
BLRX : 1.19 (-17.93%)
Alnylam Files Clinical Trial Application for ALN-AAT02 in UK

Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.

LGND : 198.64 (-2.15%)
CLBS : 4.61 (+0.77%)
ALNY : 79.29 (-2.42%)
ATHX : 2.06 (-2.37%)
Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo

Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).

LGND : 198.64 (-2.15%)
CELG : 82.70 (-1.87%)
ATHX : 2.06 (-2.37%)
AMGN : 201.97 (-0.39%)
Medicines Company to Continue Inclisiran Studies as Planned

The Medicines Company (MDCO) gets Independent Data Monitoring Committee's recommendation to continue late-stage inclisiran studies as planned and designed.

LGND : 198.64 (-2.15%)
MDCO : 26.97 (-2.88%)
ALNY : 79.29 (-2.42%)
ATHX : 2.06 (-2.37%)
Global Stem Cell Market Expected to Reach $270.5 Billion

HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from...

CRSP : 37.15 (-6.52%)
ARNA : 40.29 (-2.09%)
ATHX : 2.06 (-2.37%)
Athersys to Present at 2018 Cell & Gene Meeting on the Mesa

CEO invited to provide corporate overview and speak in two workshops focusing on innovative development initiatives in Japan and advanced manufacturing technologies

ATHX : 2.06 (-2.37%)
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

CELG : 82.70 (-1.87%)
ILMN : 322.95 (-1.83%)
ACHN : 3.00 (-3.23%)
ATHX : 2.06 (-2.37%)
IPOs and Foreign Investment Propel Biotech: 4 Top Picks

A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.

CELG : 82.70 (-1.87%)
TBIO : 7.00 (+1.74%)
ACHN : 3.00 (-3.23%)
ILMN : 322.95 (-1.83%)
NTGN : 7.95 (-0.62%)
ATHX : 2.06 (-2.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATHX with:

Business Summary

Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the...

See More

Key Turning Points

2nd Resistance Point 2.20
1st Resistance Point 2.16
Last Price 2.06
1st Support Level 2.08
2nd Support Level 2.04

See More

52-Week High 3.09
Fibonacci 61.8% 2.40
Fibonacci 50% 2.19
Last Price 2.06
Fibonacci 38.2% 1.98
52-Week Low 1.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar